Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lutetium 177Lu meO-DOTA-7E11
- Development stage
- Phase 1
- Lead developer
- EUSA Pharma
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Lutetium 177Lu meO-DOTA-7E11 is an experimental radiolabeled anti-PSMA monoclonal antibody conjugate in which the 7E11 antibody is chelated with meO-DOTA and labeled with the beta/gamma-emitting radionuclide lutetium-177, designed for targeted radioimmunotherapy and imaging of prostate cancer expressing prostate-specific membrane antigen (PSMA). Preclinical studies demonstrated preserved PSMA binding of the 7E11 conjugate, efficient Lu-177 radiolabeling, favorable pharmacokinetics with tumor uptake and retention in LNCaP xenografts, and acceptable acute toxicology in rodents and dogs. A phase I study (177Lu-CYT-500) was initiated to evaluate safety, tolerability, and dosing in patients with advanced prostate cancer.[2][5][8]
- Other names
- lutetium Lu-177 meO-DOTA-7E11lutetium-177 DOTA-7E11lutetium177 DOTA-7E11lutetium 177 DOTA-7E11177Lu-DOTA-7E11/CYT500
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on lutetium 177Lu meO-DOTA-7E11.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lutetium 177Lu meO-DOTA-7E11.